Breaking News Instant updates and real-time market news.

CGC

Canopy Growth

$33.64

4.01 (13.53%)

, CZR

Caesars

$7.78

0.28 (3.73%)

07:35
01/10/19
01/10
07:35
01/10/19
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Wednesday in Canopy Growth (CGC), Caesars (CZR), XPO Logistics (XPO), Cenovus Energy (CVE), Ctrip.com (CTRP), Hecla Mining (HL), Sea Limited (SE), BorgWarner (BWA), and ProPetro Holding (PUMP).

CGC

Canopy Growth

$33.64

4.01 (13.53%)

CZR

Caesars

$7.78

0.28 (3.73%)

XPO

XPO Logistics

$62.01

1.7 (2.82%)

CVE

Cenovus Energy

$8.11

0.22 (2.79%)

CTRP

Ctrip

$30.17

0.7 (2.38%)

HL

Hecla Mining

$2.93

0.15 (5.40%)

SE

Sea Limited

$12.49

0.18 (1.46%)

BWA

BorgWarner

$38.70

1.29 (3.45%)

PUMP

ProPetro Holding

$14.56

1 (7.37%)

  • 10

    Jan

  • 15

    Jan

  • 10

    Feb

  • 18

    Feb

CGC Canopy Growth
$33.64

4.01 (13.53%)

01/09/19
PIPR
01/09/19
INITIATION
Target $40
PIPR
Overweight
Canopy Growth initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Michael Lavery started Canopy Growth with an Overweight rating and $40 price target. The analyst expects "strong" sales growth from the company, driven by "strong sustainable category momentum." Canopy's capacity advantages, beverage partnership, and balance sheet position it well over the near-term, Lavery tells investors in a research note. He also believes the company's clinical trials and intellectual property should add competitive advantages longer term.
01/09/19
PIPR
01/09/19
INITIATION
PIPR
Overweight
Piper Jaffray rolls out bullish research coverage on Canopy Growth, Tilray
Piper Jaffray analyst Michael Lavery initiated coverage of Canopy Growth (CGC) and Tilray (TLRY) with Overweight ratings and price targets of $40 and $90, respectively. The analyst believes the global Cannabis market has the potential to reach $250B-$500B over the long term and $15B-$50B in the near term. The industry's long-term growth opportunities are significant, both from transitioning illicit trade to legal sales and from transitioning sales in health and wellness categories to cannabidiol-infused products, Lavery tells investors in a research note. The analyst expects recreational use to source from illicit trade and alcohol, medical use to source from other medical treatments, and non-psychoactive CBD-infused cannabis products to source users from food, beverage, and personal care categories. Over 25 countries have legal marijuana use today, he points out. Lavery believes federal legalization in the U.S. could potentially come in the next five years. Further, the analyst expects capital flow into the sector will likely continue.
01/04/19
WELS
01/04/19
NO CHANGE
Target $260
WELS
Outperform
Constellation 'one of the most attractive stocks' in Staples, says Wells Fargo
Wells Fargo analyst Bonnie Herzog reiterated an Outperform rating and $260 price target on Constellation Brands (STZ), telling investors in a research note that she believes Constellation is one of the most attractive stocks in Staples, given scarcity of growth across the group and the pullback, which she says is "unjustified." While she expects Constellation to lower FY19 EPS guidance to reflect 25c-30c of interest expense from the increased stake in Canopy Growth (CGC), Herzog believes Q3 results may surprise to the upside based on strong performance in Nielsen scanner data through December and potential beer margin upside from lower marketing investments. She sees Q3 results as a potential positive catalyst and encourages long-term investors to accumulate positions in the stock.
01/10/19
GSCO
01/10/19
UPGRADE
Target $211
GSCO
Buy
Constellation Brands upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Judy Hong upgraded Constellation Brands (STZ) to Buy while lowering her price target for the shares to $211 from $243. The stock closed yesterday down 12.5%, or $21.57, to $150.94 post the company's Q3 earnings report. Constellation is down over 30% in the past 12 months, mostly driven by multiple contraction, Hong tells investors in a research note. The analyst reduced her estimates to reflect a "softer outlook" but sees a "compelling" risk/reward at current share levels. Her model yields a $195 per share value for the core business excluding Canopy Growth (CGC) and a consolidated price target of $211, pointing to 40% upside. Beer sales growth should remain healthy and beer margins should improve in fiscal 2020 as cost headwinds are lapped, Hong contends. Further, she believes Constellation shares could outperform even if investors assign zero value to its investment in Canopy.
CZR Caesars
$7.78

0.28 (3.73%)

11/15/18
BERN
11/15/18
INITIATION
Target $9.1
BERN
Market Perform
Caesars initiated with a Market Perform at Bernstein
Bernstein analyst Vitaly Umansky started Caesars with a Market Perform rating and $9.10 price target. The analyst notes that over the last five years, gaming stocks have gone through periods of significant underperformance, followed by significant outperformance. The last six months have been exceptionally difficult for gaming stocks as Macau growth has begun to decelerate following nearly two years of strong growth and Las Vegas has seen unexpected near-term softness, he contends. However, Umansky argues that the gaming space has shown that if investors pick the right market, the right company, at the right time, outsized returns are possible.
01/07/19
DBAB
01/07/19
NO CHANGE
DBAB
Wynn, Caesars best large-cap Gaming stocks for 2019, says Deutsche Bank
Deutsche Bank analyst Carlo Santarelli says Wynn Resorts (WYNN) and Caesars Entertainment (CZR) are the best ways to play the large-cap Gaming space in 2019. Given current valuations and fundamental expectations "that seemingly accompany those valuations," the analyst is constructive on the larger-cap Gaming names and sees a bias to the upside in the stocks.
01/02/19
UBSW
01/02/19
UPGRADE
Target $7
UBSW
Neutral
Caesars upgraded to Neutral from Sell at UBS
UBS analyst Robin Farley upgraded Caesars Entertainment to Neutral while lowering her price target for the shares to $7 from $9. The analyst says her "bearish thesis" is now priced in with the stock down 33% over the past three months. Farley believes her below-consensus view on the Las Vegas market is more factored into the stock at these levels.
11/02/18
JEFF
11/02/18
NO CHANGE
Target $11
JEFF
Hold
Jefferies lowers Caesars target to $11 after 'softness' in Q3
Jefferies analyst David Katz views the "softness" in Caesars Entertainment's Q3 results as less consequential than the announcements of a leadership change and the decision to revisit the guidance process going forward, which he believes are "undoubtedly constructive in the longer term." Nonetheless, the analyst lowered his price target for Caesars to $11 from $12 and keeps a Hold rating on the name. The positive merits of the "increasingly clearer operating story" are tempered by the capital structure and allocation, Katz tells investors in a post-earnings research note titled "Change Can Be a Good Thing."
XPO XPO Logistics
$62.01

1.7 (2.82%)

12/17/18
DBAB
12/17/18
NO CHANGE
DBAB
Buy
Deutsche says change reinforces view short seller not reflecting XPO prospects
Deutsche Bank analyst Amit Mehrotra noted that the short presentation on XPO Logistics that was published last week has been updated. The update appears to address several of the "basic calculation errors" the firm previously highlighted but, "more critically," it removes altogether certain aspects of its cash flow analysis, according to the analyst. The removal of an important point related to cash flow supports his initial conclusion that the report is not reflective of XPO's prospects, Mehrotra tells investors. He keeps a Buy rating on XPO Logistics shares.
12/17/18
LEHM
12/17/18
NO CHANGE
Target $100
LEHM
Overweight
XPO shares offer 'significant long-term upside,' says Barclays
Despite slightly weaker than expected guidance and some questionable "market research" published last week, shares of XPO Logistics have long-term value, Barclays analyst Brandon Oglenski tells investors in a research note titled "Real Work on a Real Company." The analyst says he found last week's short report on the company to have "numerous inaccuracies and likely false conclusions." XPO's cash flow generally matches reported earnings and growth is "clearly evident in recent results," says Oglenski. He finds XPO's shares to offer "significant long-term upside from current levels." The analyst keeps an Overweight rating on the stock with a $100 price target. XPO closed Friday up $7.23, or 16%, to $51.55.
12/17/18
OPCO
12/17/18
NO CHANGE
Target $96
OPCO
Outperform
XPO Logistics price target cut to $96 from $114 at Oppenheimer
Oppenheimer analyst Scott Schneeburger reiterated an Outperform rating on XPO Logistics but cut his price target to $96 from $114, citing industry multiple contraction. In a research note to investors, Schneeburger says despite a tough run of negative sentiment, XPO's fundamental story remains little changed and he views XPO's recently introduced 12%-15% 2019 adjusted EBITDA growth guidance as achievable.
01/02/19
DBAB
01/02/19
NO CHANGE
DBAB
Buy
Deutsche Bank analysis shows XPO short seller's calls hardly pan out
Shares of XPO Logistics recovered over 90% of the losses suffered following publication Spruce Point Management's short report on December 13, Deutsche Bank analyst Amit Mehrotra tells investors in a research note. The snap back is indicative of the short report being "riddled with inaccuracies and misleading statements," with no implications to the fundamental outlook for XPO shares, Mehrotra writes. The analyst's analysis of Spruce Point's over 30 short reports over the last four years shows that most of the firm's calls have not come to fruition. Further, almost two-thirds of companies targeted by the short seller have positive returns on a six-month basis, with an average return of up 19%, says Mehrotra. The analyst adds that while XPO's fundamentals are not immune to broader macro forces, he feels "strongly that the business model allows for more resilient cash flows than market participants appreciate." Mehrotra keeps a Buy rating on XPO Logistics and continues to call the company his top overall pick.
CVE Cenovus Energy
$8.11

0.22 (2.79%)

10/05/18
CIBC
10/05/18
INITIATION
CIBC
Outperformer
Cenovus Energy initiated with an Outperformer at CIBC
10/22/18
TDSI
10/22/18
UPGRADE
TDSI
Buy
Cenovus Energy upgraded to Buy from Hold at TD Securities
10/30/18
SCOT
10/30/18
UPGRADE
SCOT
Outperform
Cenovus Energy upgraded to Outperform from Sector Perform at Scotiabank
Scotiabank analyst Jason Bouvier upgraded Cenovus Energy to Outperform citing valuation, commodity outlook, and an improved strategy.
12/10/18
TUDR
12/10/18
UPGRADE
TUDR
Buy
Cenovus Energy upgraded to Buy from Hold at Tudor Pickering
CTRP Ctrip
$30.17

0.7 (2.38%)

12/12/18
MZHO
12/12/18
DOWNGRADE
MZHO
Neutral
Ctrip assumed with a Neutral at Mizuho
Mizuho analyst James Lee assumed coverage of Ctrip with a Neutral rating and $31 price target, down from the firm's prior Buy rating. He believes "the bar has been reset" for macro uncertainties and thinks competition concerns about Meituan Dianping are overstated, he tells investors.
11/09/18
11/09/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Discovery (DISCA) downgraded to In-Line from Outperform at Imperial Capital with analyst David Miller citing valuation for the downgrade with the shares up over 20% since June 26. 2. Yelp (YELP) downgraded to Market Perform from Outperform at Raymond James, to Neutral from Outperform at Wedbush, to Neutral from Overweight at JPMorgan, and to Hold from Buy at Deutsche Bank. 3. Ctrip (CTRP) downgraded to Underperform from Buy at Daiwa, to Neutral from Buy at Nomura Instinet and UBS. 4. Skyworks (SWKS) downgraded to Neutral from Buy at BofA/Merrill and B. Riley FBR, as well as to Hold from Buy at Summit Insights. 5. Synaptics (SYNA) downgraded to Sector Weight from Overweight at KeyBanc with analyst John Vinh saying his latest latest carrier survey is indicating sell-through of the iPhone XR has been disappointing, with meaningful inventory starting to accumulate in store channels. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/03/19
BNCH
01/03/19
NO CHANGE
BNCH
Activision, Canopy Growth among Best Ideas for first half of 2019 at Benchmark
Benchmark analysts selected their Best Ideas for the first half of 2019, naming 16 stocks, including: Activision Blizzard (ATVI), BioTelemetry (BEAT), Biofrontera (BFRA), Ctrip (CTRP), Huazhu Group (HTHT), II-VI (IIVI), Intevac (IVAC), LHC Group (LHCG), Meredith (MDP), Marvell (MRVL), NeoGenomics (NEO), Pegasystems (PEGA), Silicon Labs (SLAB), Varonis (VRNS), Canopy Growth (CGC) and Waitr Holdings (WTRH).
12/12/18
MZHO
12/12/18
DOWNGRADE
MZHO
Neutral
Ctrip downgraded to Neutral from Buy at Mizuho
HL Hecla Mining
$2.93

0.15 (5.40%)

01/08/19
ADAM
01/08/19
UPGRADE
Target $3
ADAM
Buy
Hecla Mining upgraded to Buy from Hold at Canaccord
Canaccord analyst Dalton Baretto upgraded Hecla Mining to Buy from Hold based on the implied return to his revised price target. Baretto raised his price target to $3.25 from $2.75 on Hecla mining shares.
09/10/18
ROTH
09/10/18
INITIATION
Target $5
ROTH
Buy
Hecla Mining initiated with a Buy at Roth Capital
Roth Capital analyst Jake Sekelsky initiated Hecla Mining with a Buy rating and $5.00 price target, citing his view that Hecla purchased Klondex Mines and its portfolio of Nevada gold assets at a discount and Klondex should serve as the next leg of the company's growth.
11/09/18
ADAM
11/09/18
UPGRADE
ADAM
Hold
Hecla Mining upgraded to Hold from Sell at Canaccord
10/11/18
ADAM
10/11/18
DOWNGRADE
Target $3
ADAM
Sell
Hecla Mining downgraded to Sell from Hold at Canaccord
Canaccord analyst Dalton Baretto downgraded Hecla Mining to Sell from Hold after updating estimates, valuation metrics, and commodity price forecasts. Based on implied returns, Baretto lowered his price target to $2.50 from $3.25 on Hecla Mining shares.
SE Sea Limited
$12.49

0.18 (1.46%)

02/21/18
PIPR
02/21/18
NO CHANGE
PIPR
Piper Jaffray expects solid Q4 from Sea Limited
Piper Jaffray analyst Michael Olson believes the combination of gross domestic product growth and internet connectivity growth, coupled with the secular rising tide in Sea Limited's core verticals will catalyze strong growth in the near-term and material profitability in the longer-term. Olsen maintained an Overweight rating and $18 price target on shares.
06/21/18
PIPR
06/21/18
NO CHANGE
Target $18
PIPR
Overweight
Sea Limited's Free Fire becoming surprise hit, says Piper Jaffray
Piper Jaffray analyst Michael Olson notes that Sea Limited's Garena segment has historically licensed 100% of content from third parties, but last year developed Free Fire internally. The title has become a surprise hit in several markets, he contends, adding that he is seeing Free Fire among the top 10 games in more than 10 countries. While the analyst does not anticipate Free Fire driving material revenue in Q2, he believes the game could be a source of 2H18 upside. Olson reiterates an Outperform rating and $18 price target on the shares.
02/28/18
STFL
02/28/18
NO CHANGE
STFL
Sea Limited poised for market share growth in 2018, says Stifel
Stifel analyst Scott Devitt called Sea Limited's Q4 results "solid" and believes the company is ready for continued market share gains in 2018 that "should enable significant strides in monetization over time." Devitt reiterated a Buy rating and $19 PT on Sea Limited shares.
11/21/18
PIPR
11/21/18
NO CHANGE
Target $18
PIPR
Overweight
Sea Limited posted 'strong' Q3 results, says Piper Jaffray
Piper Jaffray analyst Michael Olson says Sea Limited had a "strong" Q3 with revenue and adjusted EBITDA ahead of plan. The combination of GDP and connectivity growth, along with a "secular rising tide" in the company's core verticals, will drive "strong" near-term growth, followed by "material" long-term profitability, Olson tells investors in a post-earnings research note. He lowered his price target for the shares to $18 from $19 on his sum-of-the-parts valuation but maintains an Overweight rating on Sea Limited.
BWA BorgWarner
$38.70

1.29 (3.45%)

01/07/19
MSCO
01/07/19
NO CHANGE
MSCO
Morgan Stanley sees most, if not all, auto suppliers guiding below consensus
Ahead of the Detroit auto show, Morgan Stanley analyst Armintas Sinkevicius said he expects that most, if not all, auto suppliers will provide 2019 guidance that is lower than consensus. He sees the most downside risk to Visteon (VC) and Adient (ADNT), estimating that they may guide adjusted EBITDA 6.4% and 5.0% below consensus, respectively. Not everyone will provide guidance at the show, as American Axle (AXL) and Delphi Technologies (DLPH) gave guidance with Q3 earnings and Aptiv (APTV) and BorgWarner (BWA) plan to wait for Q4 earnings, added Sinkevicius. He estimates that, on average, the auto suppliers will guide to 1.5% revenue growth and -25 bps of margin contraction in 2019, adding that his concern is that the guidance provided at Detroit may not sufficiently de-risk figures. Others in the space include Lear (LEA), Tenneco (TEN) and Magna (MGA).
12/13/18
DBAB
12/13/18
INITIATION
Target $47
DBAB
Buy
BorgWarner initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Emmanuel Rosner started BorgWarner with a Buy rating and $47 price target.
12/10/18
KEYB
12/10/18
INITIATION
KEYB
Sector Weight
BorgWarner initiated with a Sector Weight at KeyBanc
KeyBanc started BorgWarner with a Sector Weight rating.
12/13/18
DBAB
12/13/18
INITIATION
DBAB
Deutsche Bank initiates auto sector with cautious view
Deutsche Bank analyst Emmanuel Rosner initiated coverage of the auto sector with a cautious view. Rosner said this view reflects "cyclical and macro risks for the industry across the globe, as well as secular pressure from the shift towards electrified vehicles and autonomous shared mobility." The analyst favors suppliers with "secular growth potential through adoption of their technology," and as such, initiated Aptiv (APTV) and BorgWarner (BWA) with Buy ratings. Rosner also saw value in "suppliers that can maintain organic growth through share gains or favorable end-markets, and have favorable operational track record," and as such, initiated Dana Inc (DAN) and Lear Corporation (LEA) with Buy ratings. The analyst also started General Motors (GM) and Ford (F) with Buy ratings, citing "large potential upside from restructuring and portfolio decisions, favorable product mix and cycle, and value optionality from their efforts in Mobility." Rosner said he was negative on stocks facing secular pressure or market share loss, adding that he sees downside risk in Autoliv (ALV) and Veoneer (VNE), which he initiated with Sell ratings.
PUMP ProPetro Holding
$14.56

1 (7.37%)

12/21/18
OTRG
12/21/18
DOWNGRADE
OTRG
Negative
ProPetro Holding downgraded to Negative from Mixed at OTR Global
12/21/18
OTRG
12/21/18
NO CHANGE
OTRG
Pressure Pumping & Completions sector downgraded to Negative at OTR Global
OTR Global downgraded the Pressure Pumping and Completions sector to Negative from Mixed following checks that indicate Major shale E&Ps are lowering 2019 capex plans year-over-year, leading to reduced completion budgets and increasing competition among oilfield service groups.
01/08/19
TUDR
01/08/19
UPGRADE
TUDR
Buy
ProPetro Holding upgraded to Buy from Hold at Tudor Pickering
01/07/19
JRCO
01/07/19
UPGRADE
JRCO
Buy
ProPetro Holding upgraded to Buy from Hold at Johnson Rice

TODAY'S FREE FLY STORIES

AUPH

Aurinia Pharmaceuticals

$7.54

0.11 (1.48%)

07:05
01/22/19
01/22
07:05
01/22/19
07:05
Hot Stocks
Aurinia says VOS demonstrates statistically superior efficacy versus Restasis »

Aurinia Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

07:05
01/22/19
01/22
07:05
01/22/19
07:05
General news
Global stock markets under pressure after gloomy IMF report. »

Global stock markets…

BG

Bunge

$52.95

0.745 (1.43%)

07:04
01/22/19
01/22
07:04
01/22/19
07:04
Hot Stocks
Bunge sees FY18 total segment adjusted EBIT below previously disclosed range »

The company provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPGP

IPG Photonics

$132.54

3.37 (2.61%)

07:04
01/22/19
01/22
07:04
01/22/19
07:04
Hot Stocks
IPG Photonics to acquire Padtec SND »

IPG Photonics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$126.64

1.37 (1.09%)

07:04
01/22/19
01/22
07:04
01/22/19
07:04
Hot Stocks
Centene subsidiary selected by Arizona's Department of Corrections »

Centene announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 28

    May

QURE

uniQure

$31.29

-0.02 (-0.06%)

07:04
01/22/19
01/22
07:04
01/22/19
07:04
Hot Stocks
uniQure announces FDA clearance of AMT-130 NDA in Huntington's disease »

uniQure N.V. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNCE

Concert Pharmaceuticals

$14.21

-0.065 (-0.46%)

07:04
01/22/19
01/22
07:04
01/22/19
07:04
Hot Stocks
Concert completes enrollment of 12 mg cohort in CTP-543 Phase 2a trial »

Concert Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 30

    Jan

  • 12

    Feb

  • 13

    Feb

RCKT

Rocket Pharmaceuticals

$16.00

0.23 (1.46%)

07:03
01/22/19
01/22
07:03
01/22/19
07:03
Hot Stocks
Rocket Pharmaceuticals announces FDA clearance of IND application for RP-A501 »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSTI

Pluristem

$1.12

(0.00%)

07:03
01/22/19
01/22
07:03
01/22/19
07:03
Hot Stocks
Pluristem to collaborate with IDF in treatment of burn injuries »

Pluristem Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRY

Tilray

$77.14

-6.17 (-7.41%)

07:02
01/22/19
01/22
07:02
01/22/19
07:02
Hot Stocks
Tilray to acquire Natura Naturals for up to C$70M »

Tilray announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BG

Bunge

$52.95

0.745 (1.43%)

, CAG

Conagra Brands

$21.58

0.34 (1.60%)

07:02
01/22/19
01/22
07:02
01/22/19
07:02
Hot Stocks
Bunge names Gregory Heckman as acting CEO »

Bunge (BG) announced that…

BG

Bunge

$52.95

0.745 (1.43%)

CAG

Conagra Brands

$21.58

0.34 (1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

CGEN

Compugen

$3.18

0.07 (2.25%)

07:02
01/22/19
01/22
07:02
01/22/19
07:02
Hot Stocks
Compugen announces publication of preclinical data on PVRIG »

Compugen announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSU

Kansas City Southern

$110.57

6.4 (6.14%)

07:00
01/22/19
01/22
07:00
01/22/19
07:00
Recommendations
Kansas City Southern analyst commentary  »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRV

Travelers

$123.97

1.03 (0.84%)

06:58
01/22/19
01/22
06:58
01/22/19
06:58
Hot Stocks
Travelers reports Q4 consolidated combined ratio of 97.5% »

Fourth quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

TRV

Travelers

$123.97

1.03 (0.84%)

06:58
01/22/19
01/22
06:58
01/22/19
06:58
Hot Stocks
Travelers reports Q4 book value per share $86.84 »

Book value per share of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

CONN

Conn's

$19.65

0.31 (1.60%)

06:57
01/22/19
01/22
06:57
01/22/19
06:57
Recommendations
Conn's analyst commentary  »

Conn's price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRX

Amneal Pharmaceuticals

$12.41

-0.07 (-0.56%)

06:57
01/22/19
01/22
06:57
01/22/19
06:57
Hot Stocks
Amneal Pharmaceuticals appoints Todd Branning as CFO »

Amneal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

TRV

Travelers

$123.97

1.03 (0.84%)

06:57
01/22/19
01/22
06:57
01/22/19
06:57
Earnings
Travelers reports Q4 core EPS $2.13, consensus $2.33 »

Reports Q4 revenue $7.8B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

AINV

Apollo Investment

$14.51

-0.01 (-0.07%)

06:57
01/22/19
01/22
06:57
01/22/19
06:57
Upgrade
Apollo Investment rating change  »

Apollo Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

IDXG

Interpace Diagnostics

$1.07

(0.00%)

, LH

LabCorp

$137.67

2.42 (1.79%)

06:57
01/22/19
01/22
06:57
01/22/19
06:57
Hot Stocks
Interpace finalizes validation of third specimen of ThyGeNEX and ThyraMIR »

Interpace Diagnostics…

IDXG

Interpace Diagnostics

$1.07

(0.00%)

LH

LabCorp

$137.67

2.42 (1.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jan

  • 07

    Feb

  • 18

    May

ZBH

Zimmer Biomet

$105.33

-0.83 (-0.78%)

06:55
01/22/19
01/22
06:55
01/22/19
06:55
Recommendations
Zimmer Biomet analyst commentary  »

Zimmer Biomet price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jan

  • 01

    Feb

LCI

Lannett

$7.64

0.15 (2.00%)

06:55
01/22/19
01/22
06:55
01/22/19
06:55
Hot Stocks
Lannett enters U.S. distribution agreement for Trientine Hydrochloride Capsules »

Lannett announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

SDLP

Seadrill Partners

$1.77

0.07 (4.12%)

06:54
01/22/19
01/22
06:54
01/22/19
06:54
Hot Stocks
Seadrill Partners reduces dividend to 1c from 10c »

Seadrill Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNX

Knight-Swift

$32.69

1.005 (3.17%)

06:54
01/22/19
01/22
06:54
01/22/19
06:54
Recommendations
Knight-Swift analyst commentary  »

Knight-Swift generating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSE

Inspired Entertainment

$5.64

(0.00%)

06:53
01/22/19
01/22
06:53
01/22/19
06:53
Conference/Events
Inspired Entertainment management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.